GSK3β phosphorylation of the KLF6 tumor suppressor promotes its transactivation of p21

Oncogene

Volumn 32, Issue 38, 2013, Pages 4557-4564

  Lang, U E ^a   Kocabayoglu, P ^a   Cheng, G Z ^a   Ghiassi Nejad, Z ^a   Munoz U ^a   Vetter, D ^a   Eckstein, D A ^a   Hannivoort, R A ^a   Walsh, M J ^a   Friedman, S L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

GSK3 ; KLF6; p21; phosphorylation

Indexed keywords

ALANINE; ASPARTIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; KRUPPEL LIKE FACTOR 6; LUCIFERASE; PROTEIN P21; SERINE; TYROSINE;

ARTICLE; CANCER INHIBITION; CELL CULTURE; DEPHOSPHORYLATION; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR SIZE; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROCESSING; SITE DIRECTED MUTAGENESIS; TRANSACTIVATION; TRANSIENT TRANSFECTION; WESTERN BLOTTING; WILD TYPE;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; CONSENSUS SEQUENCE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GLYCOGEN SYNTHASE KINASE 3; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MOLECULAR SEQUENCE DATA; NEOPLASMS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS; TRANSCRIPTIONAL ACTIVATION;

EID: 84884596944     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.457     Document Type: Article

References (28)

1. Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol 2010; 7: 448-458.
2. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29: 4989-5005.
3. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997; 16: 3797-3804.
4. De La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane O et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998; 95: 8847-8851.
5. Zeng C, Wang R, Li D, Lin XJ, Wei QK, Yuan Y et al. A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma. Hepatology 2010; 52: 1702-1712.
6. Li D, Narla G, Kelley K, Albrecht JH, Eng FJ, Friedman SL. KLF6 induces growth arrest in vivo by transcriptional upregulation of p21 independent of p53.Hepatology 2000; 32(Part 2): 193.
7. Botella LM, Sanchez-Elsner T, Sanz-Rodriguez F, Kojima S, Shimada J, Guerrero-Esteo M et al. Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: Their potential role in the response to vascular injury. Blood 2002; 100: 4001-4010.
8. DiFeo A, Narla G, Camacho-Vanegas O, Nishio H, Rose SL, Buller RE et al. E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor. Oncogene 2006; 25: 6026-6031.
9. Li D, Yea S, Li S, Chen Z, Narla G, Banck M et al. Kruppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1. J Biol Chem 2005; 280: 26941-26952.
10. Lee UE, Ghiassi-Nejad Z, Paris AJ, Yea S, Narla G, Walsh M et al. Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene. FEBS Lett 2010; 584: 1006-1010.
11. Kremer-Tal S, Narla G, Chen Y, Hod E, Difeo A, Yea S et al. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol 2007; 46: 645-654.
12. Narla G, Kremer-Tal S, Matsumoto N, Zhao X, Yao S, Kelley K et al. In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. Oncogene 2007; 26: 4428-4434.
13. Pan XC, Chen Z, Chen F, Chen XH, Jin HY, Xu XY. Inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) by mutation or decreased expression in hepatocellular carcinomas. J Zhejiang Univ Sci B 2006; 7: 830-836.
14. Li D, Yea S, Dolios G, Martignetti JA, Narla G, Wang R et al. Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation. Cancer Res 2005; 65: 9216-9225.
15. Warke VG, Nambiar MP, Krishnan S, Tenbrock K, Geller DA, Koritschoner NP et al. Transcriptional activation of the human inducible nitric-oxide synthase promoter by Kruppel-like factor 6. J Biol Chem 2003; 278: 14812-14819.
16. Kremer-Tal S, Reeves HL, Narla G, Thung SN, Schwartz M, Difeo A et al. Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology 2004; 40: 1047-1052.
17. Reeves HL, Narla G, Ogunbiyi O, Haq AI, Katz A, Benzeno S et al. Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology 2004; 126: 1090-1103.
18. Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001; 294: 2563-2566.
19. Liu N, Li H, Li S, Shen M, Xiao N, Chen Y et al. The Fbw7/hCDC4 tumor suppressor targets pro-proliferative factor KLF5 for ubiquitination and degradation through multiple phosphodegron motifs. J Biol Chem 2010; 285: 18858-18867.
20. Banck MS, Beaven SW, Narla G, Walsh MJ, Friedman SL, Beutler AS. KLF6 degradation after apoptotic DNA damage. FEBS Lett 2006; 580: 6981-6986.
21. Slavin DA, Koritschoner NP, Prieto CC, Lopez-Diaz FJ, Chatton B, Bocco JL. A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-Jun protooncoprotein function. Oncogene 2004; 23: 8196-8205.
22. Rodriguez E, Aburjania N, Priedigkeit NM, DiFeo A, Martignetti JA. Nucleo-cytoplasmic localization domains regulate Kruppel-like factor 6 (KLF6) protein stability and tumor suppressor function. PLoS One 2010; 5: 9.
23. Reeves HL, Narla G, Arthur MJP, Tal-Kremer S, Katz A, Benzeno S et al. Mutations of Kruppel-like factor 6 (KLF6) in HCC abrogate transcriptional activation of p21/WAF and repression of both the EGF-R and MMP-2, leading to increased cell growth. Hepatology 2003; 2002.
24. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 144: 646-674.
25. Benzeno S, Narla G, Allina J, Cheng GZ, Reeves HL, Banck MS et al. Cyclindependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1. Cancer Res 2004; 64: 3885-3891.
26. Huang HD, Lee TY, Tzeng SW, Horng JT. KinasePhos: A web tool for identifying protein kinase-specific phosphorylation sites. Nucleic Acids Res 2005; 33: W226-W229.
27. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108: 837-847.
28. Nejak-Bowen KN, Monga SP. Beta-catenin signaling, liver regeneration and hepatocellular cancer: Sorting the good from the bad. Semin Cancer Biol 2011; 21: 44-58.